Seth H.Z. Fischer

Chief Executive Officer

Seth H. Z. Fischer has served as the Chief Executive Officer and as a director of the Company since September 3, 2013. Mr. Fischer served in positions of increasing responsibility with Johnson & Johnson, a public healthcare company, from 1983 until his retirement in 2012. Most recently, Mr. Fischer served as Company Group Chairman, Johnson & Johnson, and Worldwide Franchise Chairman, Cordis Corporation, from 2008 to 2012, which included responsibility for Cordis and Biosense Webster, and as Company Group Chairman, North America Pharmaceuticals from 2004 to 2007, which included responsibility for Ortho McNeil Pharmaceuticals, Janssen and Scios. Prior to this position, Mr. Fischer served as President of Ortho McNeil Pharmaceuticals from 2000 to 2004, with his operating responsibilities encompassing the commercialization of products in multiple therapeutic categories including Topamax® for epilepsy and migraine and products in the analgesic, anti infective, cardiovascular, neurologic, psychiatric and women’s health areas. Mr. Fischer has served on the board of BioSig Technologies, Inc., a public medical device company, since 2013. He has also served on the board of Agile Therapeutics, Inc., a public pharmaceutical company, since July 2016, and on the board of Marinus Pharmaceuticals, Inc., a public biopharmaceutical company, since September 2016. From April 2013 to September 2013, Mr. Fischer served on the board of Trius Therapeutics, Inc., a public pharmaceutical company, until it was acquired by Cubist Pharmaceuticals. Mr. Fischer holds a Bachelor of General Studies from Ohio University and served as a captain in the U.S. Air Force.


John L. Slebir, Esq.

Senior Vice President Business Development and General Counsel

John L. Slebir, Esq. joined VIVUS in September 2009. Since January 2014, Mr. Slebir has served as our Senior Vice President, Business Development and General Counsel, and, since June 2012, he also has served as our Secretary. From June 2011 until January 2014, Mr. Slebir served as our Vice President, Business Development and General Counsel, from January 2011 until June 2011, he served as our Vice President, General Counsel, and, from September 2009 until January 2011, he served as our General Counsel on a part-time basis. From March 1999 to January 2011, Mr. Slebir served as an attorney at Wilson Sonsini Goodrich & Rosati, P.C., specializing in corporate securities and corporate governance. Prior to joining Wilson Sonsini Goodrich & Rosati, P.C., Mr. Slebir was an attorney at two prominent Bay Area law firms specialized in insurance defense litigation. Mr. Slebir holds a B.A. in Communications from San Diego State University and a J.D. from Santa Clara University School of Law.


Mark K. Oki

Chief Financial Officer and Chief Accounting Officer

Mr. Oki has been Chief Financial Officer and Chief Accounting Officer since October 2015. Prior to joining VIVUS, Mr. Oki served as Chief Financial Officer of Alexza Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from July 2012 to October 2015, as Principal Accounting Officer from May 2010 to October 2015, as Principal Financial Officer and Secretary from December 2011 to October 2015, as Vice President, Finance and Controller from February 2010 to July 2012, and as Controller from April 2006 to February 2010. From June 2001 to April 2006, Mr. Oki served as the Controller of Pharmacyclics, Inc., a publicly traded development stage pharmaceutical company. From 1998 to 2001, Mr. Oki held several positions at Incyte Genomics, Inc., now Incyte Corporation, a publicly traded company, including most recently as Assistant Controller. From 1992 to 1997, he held several positions at Deloitte & Touche LLP, a public accounting firm. Mr. Oki received a B.S. in Business Administration with a concentration in Accounting from San Jose State University.


Santosh T. Varghese, MD

Chief Medical Officer

Dr. Varghese has been the company’s Chief Medical Officer since January 2016. From October 2013 to December 2015, Dr. Varghese served as the company’s Vice President, Medical & Regulatory Affairs, Pharacovigilance, and QA. He joined the company in March 2012 as Vice President, Head of Medical Affairs. Prior to joining the company, Dr. Varghese was Senior Vice President, Medical Affairs at Élan Pharmaceuticals where he lead Medical Affairs teams responsible for the BioNeurology portfolio. He held the position of Vice President Primary Care & Cardiovascular in Global Medical Affairs at Schering-Plough/Merck, and also held senior roles at Aventis/Sanofi-Aventis where he contributed to both US and global brand strategy and tactics. Dr. Varghese has served on the Board of Directors of the American Lung Association - New York, and was on faculty at Touro University College of Medicine. Dr. Varghese earned his M.D. from St. George's University School of Medicine, and B.S. in Biology from Pennsylvania State University. He completed his medical training in the Caribbean, United States, and United Kingdom.

Ted Broman

Vice President, Chemistry, Manufacturing and Control

Mr. Broman has been Vice President, Chemistry, Manufacturing and Control since February 2009. Mr. Broman joined VIVUS in January 2006 as Senior Director, Chemistry, Manufacturing, and Control. Prior to joining VIVUS, Mr. Broman was Executive Director, Project Management at Durect, Inc. from 2001 to 2005. From 1994 to 2001, Mr. Broman held Senior Management positions in Operation and Project Management at Matrix Pharmaceutical, Inc. From 1988 to 1994 he was Director, Analytical Services at Cygnus, Inc. and from 1976 to 1988, Mr. Broman served in several positions in Syntex Laboratories, Syntex Chemicals Group, Corporate Quality Assurance, and Corporate Technical Services. Mr. Broman has a B.A. in Biochemistry and Molecular Biology from the University of California, Santa Barbara.


Deborah Larsen

Chief Commercial Officer

Ms. Larsen has been Vice President, Marketing since January 2016, overseeing Consumer and Professional Communications, Market Access and Business Analytics.  She joined VIVUS in February 2015 as Director of Marketing.  Prior to joining VIVUS, Ms. Larsen held Global Marketing roles with GSK Consumer Healthcare from 2007 to 2014, with a leadership role in the obesity business since 2010.  From 1996 to 2007, Ms. Larsen held the position of Sr. V.P., Management Supervisor at ICC, a Healthcare Communications Agency based in New Jersey.  From 1987 to 1996, Ms. Larsen served in several Marketing and Brand Management positions at Novartis.  From 2013 to 2014, Ms. Larsen also served on the Board of Directors for the Healthcare Businesswomen’s Association (HBA) Metro Chapter.  Ms. Larsen has a B.S. in Biology from Ramapo College of New Jersey and an M.B.A. from Fairleigh Dickinson University.

Sandra E. Wells, Ph.D.

Vice President, Patents and Assistant General Counsel

Dr. Wells has been Vice President, Patents and Assistant General Counsel since January 2014. From June 2012 to December 2013, Dr. Wells served as the Senior Director of Legal Affairs. Prior to joining VIVUS, Dr. Wells was in-house counsel at Affymetrix, Inc. from 2002 to 2012, serving as Vice President and Chief Intellectual Property Counsel from 2008 to 2012. In this role she was responsible for overseeing the company’s patent and trademark portfolios and managing patent litigation. Dr. Wells received her B.A. in biology from Whitman College, her Ph.D. in Molecular Biology from U.C. Santa Cruz and completed postdoctoral studies in the department of Molecular and Cellular Biology at U.C. Berkeley where she was a Jane Coffin Childs Fellow. She received her J.D. from Santa Clara University School of Law and has been admitted to practice in California and before the U.S. Patent and Trademark Office.